Hyundai Bioscience Co Ltd
KOSDAQ:048410
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
13 900
30 700
|
Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one Hyundai Bioscience Co Ltd stock under the Base Case scenario is 501.94 KRW. Compared to the current market price of 14 490 KRW, Hyundai Bioscience Co Ltd is Overvalued by 97%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Hyundai Bioscience Co Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for Hyundai Bioscience Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Hyundai Bioscience Co Ltd
Balance Sheet Decomposition
Hyundai Bioscience Co Ltd
Current Assets | 16.2B |
Cash & Short-Term Investments | 3.9B |
Receivables | 5.5B |
Other Current Assets | 6.8B |
Non-Current Assets | 37.6B |
Long-Term Investments | 1.6B |
PP&E | 2.8B |
Intangibles | 31.2B |
Other Non-Current Assets | 2B |
Current Liabilities | 6.7B |
Accounts Payable | 407m |
Accrued Liabilities | 228.6m |
Short-Term Debt | 5.4B |
Other Current Liabilities | 681.4m |
Non-Current Liabilities | 602.9m |
Long-Term Debt | 9.2m |
Other Non-Current Liabilities | 593.7m |
Earnings Waterfall
Hyundai Bioscience Co Ltd
Revenue
|
9.2B
KRW
|
Cost of Revenue
|
-5B
KRW
|
Gross Profit
|
4.3B
KRW
|
Operating Expenses
|
-12.5B
KRW
|
Operating Income
|
-8.2B
KRW
|
Other Expenses
|
1.6B
KRW
|
Net Income
|
-6.6B
KRW
|
Free Cash Flow Analysis
Hyundai Bioscience Co Ltd
KRW | |
Free Cash Flow | KRW |
Profitability Score
Profitability Due Diligence
Hyundai Bioscience Co Ltd's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Hyundai Bioscience Co Ltd's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Hyundai Bioscience Co Ltd's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Score
Hyundai Bioscience Co Ltd's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Hyundai Bioscience Co Ltd
Dividends
Current shareholder yield for Hyundai Bioscience Co Ltd is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
HYUNDAI BIOSCIENCE Co., Ltd. engages in the manufacture and sale of bio-cosmetics and hair tonics. The company is headquartered in Gimcheon, Gyeongsangbuk-Do. The company went IPO on 2002-08-08. The company develops functional daily necessities such as shampoos, mask packs, creams, and tumor-targeted drug. The firm also sells liquid crystal display (LCD) monitors and digital signage display products. The firm distributes its products in domestic market, as well as to the overseas markets, including Europe, America and Japan.
Contact
IPO
Employees
Officers
The intrinsic value of one Hyundai Bioscience Co Ltd stock under the Base Case scenario is 501.94 KRW.
Compared to the current market price of 14 490 KRW, Hyundai Bioscience Co Ltd is Overvalued by 97%.